GMA News Online on MSN4h
PhilHealth endorses '5 better benefit packages'
The Philippine Health Insurance Corporation (PhilHealth) endorsed five 'better benefit packages' for heart attacks, rare ...
Manila Bulletin11h
5 ‘better’ benefit packages endorsed by PhilHealth committee for approval
The Department of Health (DOH) on Friday, Nov. 15, announced that the Benefits Committee (BenCom) of the Philippine Health ...
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
In the preceding three months, 8 analysts have released ratings for Amicus Therapeutics FOLD, presenting a wide array of ...
Managed Healthcare Executive1d
Small-Molecules Are More Cost Effective Than Biologics, Tufts Researchers Find
Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction ...
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Sanofi's Gaucher Initiative Marks 25 Years Of Rare Disease Care In Egypt
Sanofi, through its philanthropic organisation Foundation S, is celebrating the 25th anniversary of The Gaucher Initiative, a ...
pharmaphorum5d
Sanofi extends its Pompe range with first Nexviazyme OK
Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...
Pharmabiz6d
AskBio receives US FDA rare paediatric disease & orphan-drug designations for AB-1003 to treat limb-girdle muscular dystrophy type 2I/R9
Research Triangle Park, North Carolina Saturday, November 9, 2024, 13:00 Hrs [IST] ...
Promising Potential and Strong Safety Profile Drive Buy Rating for Tectonic Therapeutic
Wells Fargo analyst Tiago Fauth has maintained their bullish stance on TECX stock, giving a Buy rating yesterday. Tiago Fauth has given his ...
Tectonic Therapeutic: Promising Phase 1a Results and Strong Financial Health Justify Buy Rating
In a report released on November 8, David Risinger from Leerink Partners maintained a Buy rating on Tectonic Therapeutic (TECX – Research ...
pharmaphorum3d
FDA experts to vote on Spark's groundbreaking gene therapy
But he said the company will use price of drugs for other ultra-rare diseases such as Pompe disease, and Hunter Syndrome, suggesting a price in the range of $300,000 - $600,000 per year.